Trial Profile
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Dec 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms PsOsim
- Sponsors Coherus Biosciences
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 20 Dec 2021 According to a Coherus Biosciences media release, the United States Food and Drug Administration (FDA) approved YUSIMRY (adalimumab-aqvh), formerly CHS-1420, a Humira (adalimumab) biosimilar product. Approval was based on a comprehensive data package that demonstrated the biosimilarity of YUSIMRY to the reference product, Humira. Data included results from Study CHS-1420-02 and CHS-1420-03
- 05 Aug 2021 According to a Coherus Biosciences media release, the review of the CHS-1420 BLA is progressing with a target action date of December 2021.